Federal Circuit Affirms Unpatentability — Five Pharma Patents, 88-Day Appeal
In Case No. 23-1186, the Court of Appeals for the Federal Circuit affirmed a finding of unpatentability across five patents covering controlled release dosage forms and sensitive drug distribution systems. The appeal was resolved in 88 days, an unusually swift disposition for a multi-patent Federal Circuit matter.
Five Pharma Patents Invalidated: Federal Circuit Affirms Unpatentability
Case No. 23-1186 was an infringement action appeal heard by the Court of Appeals for the Federal Circuit in the District of Columbia circuit. Five patents were at issue: US10966931B2, US8731963B1, US10758488B2, US10959956B2, and US10813885B1, each relating to controlled release dosage forms for high dose, water soluble and hygroscopic drug substances and a sensitive drug distribution system and method. The appeal was filed on 28 November 2022.
The Federal Circuit issued a terse but decisive order — 'THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED' — on 24 February 2023, 88 days after the appeal was docketed. The recorded Basis of Termination is 'Unpatentable', meaning the court affirmed the underlying determination that the challenged patents do not meet statutory patentability requirements. The specific grounds of unpatentability are not elaborated in the available record.
The 88-day resolution is notably compressed for a multi-patent Federal Circuit appeal and suggests the panel found the unpatentability finding well-supported with no close legal questions warranting extended briefing or argument. What precise grounds — anticipation, obviousness, or otherwise — underpinned the ruling is not disclosed in the available public record, nor are the identities of the parties, leaving the full commercial context of the decision opaque to third-party observers.
See Complete Case & Patent Analysis →Filing to Unpatentable in 88 days
88 days — fast disposition for a five-patent Federal Circuit appeal
US10966931B2 and four related patents — controlled release drug formulation
Any pharmaceutical manufacturer, generic developer, or contract development and manufacturing organisation (CDMO) working with controlled release dosage forms for high dose, water soluble or hygroscopic active pharmaceutical ingredients should assess this patent family. Although the Federal Circuit has affirmed unpatentability of these five specific patents, related continuation, divisional, or foreign counterpart applications may remain active and could present residual risk for products in this formulation category.
Official order — verbatim text
The Federal Circuit's order — 'AFFIRMED' without further elaboration — is consistent with a panel that found the unpatentability determination below free from legal or factual error. The Basis of Termination recorded as 'Unpatentable' aligns with the appellate affirmance: the lower-level invalidity finding across all five patents survives appellate scrutiny and is now final at this court level. The terse order style is common where the panel finds the record dispositive and no precedential legal question warrants extended opinion.
Federal Circuit affirms: what the ruling means for both parties
What 'Affirmed' means at the Federal Circuit
An affirmance by the Federal Circuit means the appellate panel found no reversible error in the tribunal below. The prior unpatentability determination — covering all five patents — now stands as final appellate authority. The appellant has exhausted Federal Circuit review at this level; further recourse would require a petition for certiorari to the Supreme Court, which is rarely granted in patent validity disputes.
No reversible error foundAll five patents confirmed unpatentable — enforceability extinguished
The affirmance means the appellant's portfolio of five patents covering controlled release dosage forms and the sensitive drug distribution system can no longer be enforced. Any pending or contemplated infringement actions grounded in these patents are foreclosed. The patent holder's exclusivity position in this technology segment is effectively eliminated by the ruling.
Patents unenforceableAppellee secures definitive freedom from these five patents
The party that successfully challenged patentability now holds Federal Circuit-affirmed protection against these five patents. With the unpatentability finding affirmed, the challenger and the broader market are no longer exposed to infringement risk under this specific portfolio. The high bar for Supreme Court certiorari means this outcome is, in practical terms, final.
Challenger prevailsControlled release drug-form IP landscape: barrier reduced
Affirmance of unpatentability across five patents in the controlled release and hygroscopic drug-form space signals that these particular technical approaches are now free from patent exclusivity. Competitors and generic developers working in high dose, water soluble formulation technology should note that this cluster of patents no longer represents a blocking position. R&D teams should verify which specific claims were invalidated before concluding freedom to operate.
IP barrier removedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Plaintiff | Individual | Appellant — holder of five patents covering controlled release and drug distribution technologySearch in Eureka ↗ |
| Defendant | Defendant | Individual | Appellee — prevailed on unpatentability of controlled release and drug distribution patentsSearch in Eureka ↗ |
| Presiding judge | Judge Gregory Brian Williams | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
R&D signals: controlled release and drug distribution formulation IP
Forward-looking patent and innovation intelligence in the controlled release dosage form and sensitive drug distribution space — relevant to pharma R&D and formulation teams monitoring this ruling.
Filing activity in controlled release hygroscopic drug formulations
The five-patent portfolio at issue — centred on US10966931B2 and related applications — represents a cluster of filings across multiple prosecution cycles targeting hygroscopic and water-soluble drug dosage forms. Monitoring continuation and divisional activity from these application numbers can reveal whether the original filer is rebuilding exclusivity through surviving family members after this affirmance.
Portfolio continuationsTrends in high dose, water-soluble oral drug formulation patents
High dose, water-soluble and hygroscopic active pharmaceutical ingredient formulation is an active area of patent filings, particularly as polymer-based and matrix-controlled release technologies evolve. Tracking filing trends in IPC/CPC classes covering modified release solid dosage forms can identify where innovation concentration is shifting following the invalidation of these five patents.
Formulation filing trendsAppellee's patent position in drug distribution systems
The party that successfully challenged these five patents — identity not disclosed in the available record — likely holds or is developing its own IP position in sensitive drug distribution and controlled release technology. Analysing the appellee's filing activity in drug distribution system and method patents can surface competitive positioning and potential blocking positions they are building around the now-invalidated claims.
Competitor filing activityOpen claim space post-invalidation: what formulation engineers can now file
With US10813885B1 and US10758488B2 — covering drug distribution methods and controlled release forms — confirmed unpatentable, adjacent technical approaches previously constrained by these claims may now represent finable white space. R&D teams should assess novel excipient combinations, moisture-barrier coatings, and distribution mechanism refinements that previously risked overlap with these now-invalidated patents.
Post-invalidation white spaceSimilar Federal Circuit appeals: controlled release and drug formulation patents
Browse Federal Circuit appeals with comparable unpatentability affirmances in controlled release dosage form and pharmaceutical distribution patent disputes.
What this case signals for the controlled release pharma IP landscape
A five-patent affirmance of unpatentability at the Federal Circuit in under 90 days carries clear signals for drug formulation IP strategy.
Swift multi-patent affirmances signal weak prosecution foundations
When the Federal Circuit disposes of a five-patent appeal in 88 days, it typically suggests the unpatentability grounds below were well-established and the appellate arguments lacked sufficient differentiation. Patent holders in controlled release formulation technology should audit claim scope and prosecution history for prior art exposure before asserting portfolios.
Hygroscopic and water-soluble drug formulation space: patent risk recalibrated
Five patents covering controlled release dosage forms for high dose, hygroscopic drug substances and sensitive drug distribution methods have been confirmed unpatentable. Companies active in this formulation segment — including generic developers — should update their FTO assessments to reflect this reduced blocking position, while monitoring any continuation or divisional applications that may not be captured by this ruling.
Plaintiff v Defendant — key questions answered
The Court of Appeals for the Federal Circuit affirmed the lower-level finding of unpatentability across all five patents at issue — US10966931B2, US8731963B1, US10758488B2, US10959956B2, and US10813885B1. The Basis of Termination is recorded as 'Unpatentable'. The appeal was resolved in 88 days.
Five patents were at issue: US10966931B2, US8731963B1, US10758488B2, US10959956B2, and US10813885B1. These cover controlled release dosage forms for high dose, water soluble and hygroscopic drug substances and a sensitive drug distribution system and method. All five were affirmed unpatentable by the Federal Circuit.
An affirmance means the Federal Circuit found no reversible error in the lower-level unpatentability determination. The five patents can no longer be enforced. The appellant's further options are limited to a Supreme Court certiorari petition, which is rarely granted. The specific grounds of unpatentability — e.g. anticipation or obviousness — are not elaborated in the available public record.
The Federal Circuit's affirmance binds the five specifically appealed patents. Continuation, divisional, or foreign counterpart applications within the same patent families are not necessarily invalidated by this order. A full patent family analysis is recommended for any company active in controlled release or hygroscopic drug formulation technology to identify surviving related applications.
The 88-day resolution is compressed for a five-patent Federal Circuit appeal. This pace suggests the panel found the unpatentability determination well-supported by the record and the appellate arguments insufficient to raise a close legal question warranting extended briefing or oral argument. The specific procedural pathway — whether decided on the papers or after argument — is not detailed in the available record.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.